Effects of Nicorandil on Cardiovascular Events in Patients With Coronary Artery Disease in The Japanese Coronary Artery Disease (JCAD) Study

• Horinaka Shigeo

  Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University

• Yabe Akihisa

  Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University

• Yagi Hiroshi

  Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University

• Ishimitsu Toshihiko

  Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University

• Yamazaki Tsutomu

  Department of Clinical Epidemiology and Systems, University of Tokyo

• Suzuki Shinya

  Department of Clinical Epidemiology and Systems, University of Tokyo

• Kohro Takahide

  Department of Translational Research for Healthcare and Clinical Science, University of Tokyo

• Nagai Ryozo

  Department of Cardiovascular Medicine Graduate School of Medicine, University of Tokyo

• The JCAD Study Investigators

抄録

Background: Nicorandil has cardioprotective effects in the ischemic myocardium, mimicking ischemic preconditioning, and is thus expected to improve the prognosis of ischemic heart disease (IHD). As part of the Japanese Coronary Artery Disease (JCAD) Study, a multicenter collaborative prospective observational study of a large cohort of coronary artery disease patients, the effect of nicorandil on outcome was examined. Methods and Results: In total, 2,558 patients with nicorandil treatment and controls subjected to propensity score matching were eligible among 13,812 patients registered in the JCAD study. The mean follow-up interval was 2.7 years. The primary endpoint, death from all causes, was significantly lower, by 35% (hazard ratio 0.65, P=0.0008), in the nicorandil group than in the control group. There were also significant reductions in secondary endpoints, including cardiac death (56%), fatal myocardial infarction (56%), cerebral or vascular death (71%), and congestive heart failure (33%) in the nicorandil group, with no excess of deaths from other non-cardiovascular causes. Treatment with nicorandil reduced the number of deaths from all causes to a similar extent with or without treatment with sulfonylureas. Conclusions: The reduction in cardiovascular death with nicorandil was large in patients with IHD, which has important implications for treatment. (Circ J 2010; 74: 503 - 509)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 74 (3), 503-509, 2010

  一般社団法人 日本循環器学会

キーワード

• Cardiovascular events
• Coronary artery disease
• Japanese Coronary Artery Disease (JCAD) Study
• Nicorandil

詳細情報

• CRID: 1390282680081377792
• NII論文ID: 10025943495
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-09-0649
• ISSN: 13474820
• ISSN: 13469843
• Web Site: http://www.jstage.jst.go.jp/article/circj/74/3/74_CJ-09-0649/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2010209851
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可